Form 4: Corcept Therapeutics Executive William Guyer Executes Option and Sells Shares Under 10b5-1 Plan

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 10,000 shares of common stock on October 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On October 1, 2024, William Guyer, the Chief Development Officer of Corcept Therapeutics, exercised stock options to acquire 10,000 shares of common stock at a price of $21.65 per share.
• Simultaneously, Guyer sold 10,000 shares of Corcept Therapeutics common stock at a price of $46.28 per share.
• These transactions were executed under a pre-existing 10b5-1 trading plan.
• Following these transactions, Guyer directly owns 5,796 shares of Corcept Therapeutics common stock, which includes 609 shares underlying unvested restricted stock units.
• Guyer also holds options to purchase 460,000 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity under a pre-arranged plan. There's no indication of positive or negative implications for the company.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to use 10b5-1 plans to sell shares periodically to avoid accusations of trading on inside information. The exercise of options and subsequent sale of shares is a typical wealth management strategy for executives.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan and do not indicate a change in the executive's long-term outlook for the company.

Key Dates